{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Assessed by achievement of Complete Response (CR), Partial Response (PR) or Hematologic Improvement (HI)","groups":[{"description":"Patients will receive sunitinib by mouth once a day. Treatment may continue for as long as benefit is shown.\n\nsunitinib malate: Given orally","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","populationDescription":"No patient achieved CR, PR or HI as response.","reportingStatus":"POSTED","timeFrame":"Up to 6 years","title":"Number Participants With Complete, Partial or Hematologic Improvement Response","type":"SECONDARY","unitOfMeasure":"participants"}